Industry still facing Problems with Root Cause Investigations

Recommendation
13-16 May 2025
Copenhagen, Denmark
with 7 Workshops
Deviations and CAPA are still important issues during inspections. Inspectors' summaries of their observations show that things do not always work as they should. This also applies to root cause investigations. A look at the FDA's so-called 483s is also interesting here. The observations made by the inspector during an inspection are listed on the FDA Form 483. What many people do not know is that FDA summarises results from the 483s in tables and publishes them in their overview entitled "Inspection Observations".
According to the current file, 349 corresponding forms were issued in the area of "Drugs" in fiscal year 2020. With 79 observations, violations of section 21 CFR 211.192 ("Investigations of discrepancies, failures") are in second place. Primarily, this concerns problems and failures in the review of unexplained deviations and specifications that have not been met. The "Written record of investigation" required in the same paragraph was objected to 28 times. Here, written records of investigations do not always include conclusions and follow-up, or are not even present.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years